Patents by Inventor Thomas F. Tedder

Thomas F. Tedder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200283727
    Abstract: Provided herein are methods of expanding B cells, and in particularly B10 cells capable of producing IL-10, ex vivo. The methods include incubation of harvested B cells in the presence of IL-21. Compositions comprising the ex vivo expanded B cells and methods of using the expanded B cell-containing compositions to treat diseases or conditions are also provided. Methods of assessing B10 cell function in a subject are also provided.
    Type: Application
    Filed: March 20, 2020
    Publication date: September 10, 2020
    Applicant: DUKE UNIVERSITY
    Inventors: Thomas F. Tedder, Ayumi Yoshizaki, Tomomitsu Miyagaki, Evgueni Kountikov, Jonathan C. Poe
  • Publication number: 20200239872
    Abstract: Provided herein is an antigen display library for detecting antibodies produced by an individual; and methods of using the antigen display library to generate an antibody signature, the method comprising contacting a biological sample containing antibodies from an individual with the antigen display library, isolating phage clones displaying antigenic epitopes recognized by antibody in the sample, and identifying the antigenic epitopes that were recognized by antibody in the sample. Also provided are kits for generating an antibody signature comprising the antigen display library, a substrate for isolating phage clones bound by antibody, and may further comprise reagents useful for generating the antibody signature.
    Type: Application
    Filed: March 13, 2018
    Publication date: July 30, 2020
    Applicant: Duke University
    Inventors: Thomas F. TEDDER, Evgueni KOUNTIKOV
  • Patent number: 10611999
    Abstract: Provided herein are methods of expanding B cells, and in particularly B10 cells capable of producing IL-10, ex vivo. The methods include incubation of harvested B cells in the presence of IL-21. Compositions comprising the ex vivo expanded B cells and methods of using the expanded B cell-containing compositions to treat diseases or conditions are also provided. Methods of assessing B10 cell function in a subject are also provided.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: April 7, 2020
    Assignee: Duke University
    Inventors: Thomas F. Tedder, Ayumi Yoshizaki, Tomomitsu Miyagaki, Evgueni Kountikov, Jonathan C. Poe
  • Publication number: 20190367607
    Abstract: Provided are methods involving combination therapy comprising administering to an individual in need thereof an antibody that preferentially depletes human B10 cells and an immune checkpoint inhibitor. Antibodies for use in the methods are also provided.
    Type: Application
    Filed: June 14, 2019
    Publication date: December 5, 2019
    Applicant: Duke University
    Inventors: Thomas F. TEDDER, Yasuhiro FUJISAWA, Jacquelyn LYKKEN
  • Publication number: 20190352607
    Abstract: Provided are feeder cell lines that can be used to expand and differentiate B cells in vitro, a method for expanding B cells in vitro comprising culturing the B cells with the feeder cell line, and a method for producing monoclonal antibody in vitro comprising culturing a single B cell with the feeder cell line under sufficient conditions and for sufficient time to induce expansion and differentiation of the B cell into a B cell done secreting antibody.
    Type: Application
    Filed: February 16, 2017
    Publication date: November 21, 2019
    Applicant: Duke University
    Inventors: Hiraku SUGA, Kathleen M. CANDANDO, Evgueni KOUNTIKOV, Masahiro KAMATA, Thomas F. TEDDER, Ayumi YOSHIZAKI, Tomomitsu MIYAGAKI
  • Publication number: 20190136185
    Abstract: The present invention relates to a distinct B cell subset, B10 cells, that regulate T cell mediated inflammatory responses through the secretion of interleukin-10 (IL-10). The invention also relates to the use of B10 cells in the manipulation of immune and inflammatory responses, and in the treatment of disease. Therapeutic approaches involving adoptive transfer of B10 cells, or expansion of their endogenous levels for controlling autoimmune or inflammatory diseases and conditions are described. Ablation of B10 cells, or inhibition of their IL-10 production can be used to upregulate immunodeficient conditions, ameliorate infectious diseases and/or to treat tumors/cancer. Diagnostic applications are also encompassed.
    Type: Application
    Filed: November 19, 2018
    Publication date: May 9, 2019
    Applicant: Duke University
    Inventors: Thomas F. Tedder, Takashi Matsushita, Yohei Iwata, Koichi Yanaba, Jean-David Bouaziz
  • Patent number: 10131875
    Abstract: The present invention relates to a distinct B cell subset, B10 cells, that regulate T cell mediated inflammatory responses through the secretion of interleukin-10 (IL-10). The invention also relates to the use of B10 cells in the manipulation of immune and inflammatory responses, and in the treatment of disease. Therapeutic approaches involving adoptive transfer of B10 cells, or expansion of their endogenous levels for controlling autoimmune or inflammatory diseases and conditions are described. Ablation of B10 cells, or inhibition of their IL-10 production can be used to upregulate immunodeficient conditions, ameliorate infectious diseases and/or to treat tumors/cancer. Diagnostic applications are also encompassed.
    Type: Grant
    Filed: August 4, 2011
    Date of Patent: November 20, 2018
    Assignee: Duke University
    Inventors: Thomas F. Tedder, Takashi Matsushita, Yohei Iwata, Koichi Yanaba, Jean-David Bouaziz
  • Publication number: 20180291340
    Abstract: Provided herein are methods of expanding B cells, and in particularly B10 cells capable of producing IL-10, ex vivo. The methods include incubation of harvested B cells in the presence of IL-21. Compositions comprising the ex vivo expanded B cells and methods of using the expanded B cell-containing compositions to treat diseases or conditions are also provided. Methods of assessing B10 cell function in a subject are also provided.
    Type: Application
    Filed: June 5, 2018
    Publication date: October 11, 2018
    Applicant: DUKE UNIVERSITY
    Inventors: Thomas F. Tedder, Ayumi Yoshizaki, Tomomitsu Miyagaki, Evgueni Kountikov, Jonathan C. Poe
  • Patent number: 10017739
    Abstract: Provided herein are methods of expanding B cells, and in particularly B10 cells capable of producing IL-10, ex vivo. The methods include incubation of harvested B cells in the presence of IL-21. Compositions comprising the ex vivo expanded B cells and methods of using the expanded B cell-containing compositions to treat diseases or conditions are also provided. Methods of assessing B10 cell function in a subject are also provided.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: July 10, 2018
    Assignee: DUKE UNIVERSITY
    Inventors: Thomas F. Tedder, Ayumi Yoshizaki, Tomomitsu Miyagaki, Evgueni Kountikov, Jonathan C. Poe
  • Patent number: 9913863
    Abstract: The present invention relates to a phenotypically distinct CD1dhighCD5+ B cell subset that regulates T cell mediated inflammatory responses through the secretion of interleukin-10 (IL-10). The invention also relates to the use of these IL-10 producing regulatory B cells in the manipulation of immune and inflammatory responses, and in the treatment of disease. Therapeutic approaches involving adoptive transfer of these regulatory B cells, or expansion of their endogenous levels for controlling autoimmune or inflammatory diseases and conditions are described. Ablation of this subset of regulatory B cells, or inhibition of their IL-10 production can be used to upregulate immunodeficient conditions, and/or to treat tumors/cancer. Diagnostic applications also are encompassed.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: March 13, 2018
    Assignee: Duke University
    Inventors: Thomas F. Tedder, Koichi Yanaba, Jean-David Bouaziz
  • Patent number: 9669057
    Abstract: The present invention relates to a phenotypically distinct CD1dhighCD5+ B cell subset that regulates T cell mediated inflammatory responses through the secretion of interleukin-10 (IL-IO). The invention also relates to the use of these IL-IO producing regulatory B cells in the manipulation of immune and inflammatory responses, and in the treatment of disease. Therapeutic approaches involving adoptive transfer of these regulatory B cells, or expansion of their endogenous levels for controlling autoimmune or inflammatory diseases and conditions are described. Ablation of this subset of regulatory B cells, or inhibition of their IL-IO production can be used to upregulate immunodeficient conditions, and/or to treat tumors/cancer. Diagnostic applications also are encompassed.
    Type: Grant
    Filed: April 27, 2009
    Date of Patent: June 6, 2017
    Assignee: Duke University
    Inventors: Thomas F. Tedder, Koichi Yanaba, Jean-David Bouaziz
  • Publication number: 20170088625
    Abstract: The present invention provides monoclonal antibodies and antigen-binding fragments thereof that specifically bind to CD20, as well as pharmaceutical compositions comprising the same. The invention further provides methods of using the monoclonal antibodies, antigen-binding fragments, and pharmaceutical compositions, for example, in methods of depleting B cells or in treating B cell disorders. Also provided are cells, nucleic acids and methods for producing the monoclonal antibodies.
    Type: Application
    Filed: July 13, 2016
    Publication date: March 30, 2017
    Inventors: Thomas F. Tedder, Junji Uchida, Yasuhito Hamaguchi, Jonathan C. Poe
  • Publication number: 20160375059
    Abstract: The present invention relates to a phenotypically distinct CD1dhighCD5+ B cell subset that regulates T cell mediated inflammatory responses through the secretion of interleukin-10 (IL-10). The invention also relates to the use of these IL-10 producing regulatory B cells in the manipulation of immune and inflammatory responses, and in the treatment of disease. Therapeutic approaches involving adoptive transfer of these regulatory B cells, or expansion of their endogenous levels for controlling autoimmune or inflammatory diseases and conditions are described. Ablation of this subset of regulatory B cells, or inhibition of their IL-10 production can be used to upregulate immunodeficient conditions, and/or to treat tumors/cancer. Diagnostic applications also are encompassed.
    Type: Application
    Filed: May 26, 2016
    Publication date: December 29, 2016
    Applicant: DUKE UNIVERSITY
    Inventors: Thomas F. Tedder, Koichi Yanaba, Jean-David Bouaziz
  • Patent number: 9416187
    Abstract: The present invention provides monoclonal antibodies and antigen-binding fragments thereof that specifically bind to CD20, as well as pharmaceutical compositions comprising the same. The invention further provides methods of using the monoclonal antibodies, antigen-binding fragments, and pharmaceutical compositions, for example, in methods of depleting B cells or in treating B cell disorders. Also provided are cells, nucleic acids and methods for producing the monoclonal antibodies.
    Type: Grant
    Filed: May 7, 2004
    Date of Patent: August 16, 2016
    Assignee: Duke University
    Inventors: Thomas F. Tedder, Yasuhito Hamaguchi, Jonathan C. Poe
  • Patent number: 9260530
    Abstract: The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies and autoimmune diseases and disorders, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.
    Type: Grant
    Filed: August 1, 2013
    Date of Patent: February 16, 2016
    Assignee: Duke University
    Inventors: Thomas F. Tedder, Yasuhito Hamaguchi, Hanne Gron, Norihito Yazawa
  • Patent number: 8734792
    Abstract: The invention concerns treatment methods using anti-CD22 monoclonal antibodies with unique physiologic properties. In particular, the invention concerns methods for the treatment of B-cell malignancies and autoimmune diseases by administering an effective amount of a blocking anti-CD22 monoclonal antibody specifically binding to the first two Ig-like domains, or to an epitope within the first two Ig-like domains of native human CD22 (hCD22).
    Type: Grant
    Filed: May 9, 2012
    Date of Patent: May 27, 2014
    Assignee: Duke University
    Inventor: Thomas F. Tedder
  • Publication number: 20140065118
    Abstract: Provided herein are methods of expanding B cells, and in particularly B10 cells capable of producing IL-10, ex vivo. The methods include incubation of harvested B cells in the presence of IL-21. Compositions comprising the ex vivo expanded B cells and methods of using the expanded B cell-containing compositions to treat diseases or conditions are also provided. Methods of assessing B10 cell function in a subject are also provided.
    Type: Application
    Filed: March 12, 2013
    Publication date: March 6, 2014
    Inventors: Thomas F. Tedder, Ayumi Yoshizaki, Tomomitsu Miyagaki, Evgueni Kountikov, Jonathan C. Poe
  • Publication number: 20140056896
    Abstract: The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies and autoimmune diseases and disorders, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.
    Type: Application
    Filed: August 1, 2013
    Publication date: February 27, 2014
    Applicant: DUKE UNIVERSITY
    Inventors: Thomas F. Tedder, Yasuhito Hamaguchi, Hanne Gron, Norihito Yazawa
  • Publication number: 20130136754
    Abstract: The present invention relates to a distinct B cell subset, B10 cells, that regulate T cell mediated inflammatory responses through the secretion of interleukin-10 (IL-10). The invention also relates to the use of B10 cells in the manipulation of immune and inflammatory responses, and in the treatment of disease. Therapeutic approaches involving adoptive transfer of B10 cells, or expansion of their endogenous levels for controlling autoimmune or inflammatory diseases and conditions are described. Ablation of B10 cells, or inhibition of their IL-10 production can be used to upregulate immunodeficient conditions, ameliorate infectious diseases and/or to treat tumors/cancer. Diagnostic applications are also encompassed.
    Type: Application
    Filed: August 4, 2011
    Publication date: May 30, 2013
    Inventors: Thomas F. Tedder, Takashi Matsushita, Yohei Iwata, Koichi Yanaba, Jean-David Bouaziz
  • Patent number: 8444973
    Abstract: The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies and autoimmune diseases and disorders, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.
    Type: Grant
    Filed: September 17, 2010
    Date of Patent: May 21, 2013
    Assignee: Duke University
    Inventors: Thomas F. Tedder, Yasuhito Hamaguchi, Hanne Gron, Norihito Yazawa